Senate Finance Committee Member Supports QALYs in Pricing Assessments

Anna Kaltenboeck, a member of the Senate Finance Committee, has publicly expressed her support for quality-adjusted life years (QALYs) as a method of determine the price of a drug. Her role on the committee could signal a push for drug pricing reform, such as the establishment of a federal health technology assessment, with QALYs becoming one component of a drug value assessment.

“Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.” Read more here.

(Source: Cathy Kelly, Pink Sheet, 5/11/21)